It still supports the reproductive market
While the regulatory move restricts who can access surrogacy, there is no prohibition on the practice of surrogacy per se. Allowing surrogacy only for heterosexual couples who are childless, and have been married for five years, is discriminatory towards people who remain outside the framework of marriage in a hetero-patriarchy—single parents, couples in a live-in relationship and queer people.
Only a few provisions of the new bill have been communicated by the government, while the bill itself is not yet in the public domain. The regulatory rationale seems to be centered on two axes—the notion of an “ideal” family and “commerce” in reproduction. In its legitimisation of “altruistic” surrogacy within “close relatives”, the bill draws upon the patriarchal assumption of women’s nature as being sacrificial and altruistic. It also seeks to bring back reproductive labour from the market to the family and household levels, which are domains where women’s labour is available as a “free” resource for consumption by “close relatives”.
If exploitation of women in the market is a concern, then their exploitation within families is also a reality that must be addressed. It remains to be seen whether the bill provides safeguards against coercion of women by family members to become surrogate mothers, as this would be yet another example of gender violence.
It is interesting that the phenomenon of commercial surrogacy is found to be objectionable only because the woman acting as the surrogate receives remuneration. Apart from this aspect, there is no difference between what is known as commercial and altruistic surrogacy. In its modern “gestational” avatar, surrogacy is marketed as an “infertility treatment” using the technique of In Vitro Fertilisation (IVF). But the broader issue, which must receive regulatory attention, is the question of how such “treatment” is administered—the use of hormonal drugs and injections, multiple IVF cycles, effects on the physical as well as mental health of women, whether informed consent has been taken from them, their right to reproductive autonomy and the relationship between the surrogate mother and the child she gives birth to. In this somewhat moralistic clamour over banning payments to surrogate mothers, adequate discussion on these issues has been sidelined.
The bill has also left out the commercial and profit-driven industry of the Assisted Reproductive Technologies (ARTs), which is overwhelmingly found in the private healthcare sector. Infertility treatment using ARTs and IVF has been available commercially in India for over three decades now. Yet there is no regulation that governs this sector. Though guidelines were formulated by the Indian Council of Medical Research in 2005, they are not legally binding. While it is important to debate surrogacy, at the same time, the ARTs industry, which drives it, must also be regulated.